Comparison of Efficacy Between Nab-Paclitaxel or Docetaxel Combined with Carboplatin as Neoadjuvant Therapy for HER2-Positive Breast Cancer
10.3971/j.issn.1000-8578.2024.24.0147
- VernacularTitle:白蛋白结合型紫杉醇或多西他赛联合卡铂新辅助治疗HER2阳性乳腺癌疗效比较
- Author:
Xin HAO
1
;
Chongzhu HU
;
Ruixue YUE
;
Tianpei MIAO
;
Zhong LI
Author Information
1. 071000 保定,河北大学附属医院乳腺外科
- Keywords:
Breast cancer;
Neoadjuvant therapy;
HER2;
Nab-paclitaxel;
Docetaxel;
Pathological complete response
- From:
Cancer Research on Prevention and Treatment
2024;51(9):779-783
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of trastuzumab plus pertuzumab(HP)combined with either nab-paclitaxel plus carboplatin or docetaxel plus carboplatin as neoadjuvant therapy for HER2-positive breast cancer in real-world clinical practice.Methods Clinical data of HER2-positive breast cancer patients who received neoadjuvant therapy with either HP combined with nab-paclitaxel plus carboplatin or HP combined with docetaxel plus carboplatin and subsequently underwent surgery were retrospectively collected from 11 tertiary grade-A hospitals in Hebei Province from June 2019 to December 2021.The total pathological complete response(tpCR)rates of the two groups were compared.Results A total of 76 patients were included in the study,with 47 in the nab-paclitaxel group and 29 in the docetaxel group.The tpCR rate was significantly higher in the nab-paclitaxel group than that in the docetaxel group(72.3%vs.48.3%,χ2=4.463,P=0.035).Subgroup analysis indicated that patients older than 40 years,with cN2-3,cTNM stage Ⅲ,hormone receptor-positive status,and Ki67>30%had significantly higher tpCR rates in the nab-paclitaxel group than those in the docetaxel group(P<0.05).Conclusion In real-world clinical practice,the efficacy of HP combined with nab-paclitaxel plus carboplatin as neoadjuvant therapy for HER2-positive breast cancer is superior to that of HP combined with docetaxel plus carboplatin.
